近日,艾伯维斥资7亿美元预付款,引进IGI Therapeutics SA(IGI)公司的三特异性抗体新药ISB 2001,在北美、欧洲、日本和大中华区开发、制造和商业化的独家权利。根据协议,IGI将获得7亿美元的预付款,并有资格获得高达12.25亿美元的开发、监管和商业里程碑付款,以及分层的两位数净销售额特许权使用费。根据公开资料,ISB 2001是一款靶向CD38、BCMA和CD3的三特异性...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.